Abbott Laboratories (ABT) has been a highly searched stock on Zacks.com, and this article provides an overview of factors influencing its near-term performance. It highlights earnings estimate revisions, revenue growth forecasts, and recent financial results as key indicators for potential investors. The stock currently holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market.

Canaccord maintained a Hold rating and an $85.00 price target on Edwards Lifesciences following a Medicare coverage decision for transcatheter aortic valve replacement (TAVR) procedures. The Centers for Medicare & Medicaid Services (CMS) formalized Medicare coverage for asymptomatic severe aortic stenosis and removed facility-level procedural volume thresholds, which is expected to drive longer-term volume growth. Despite this positive development, Canaccord notes that the implementation and adoption of the new National Coverage Determination (NCD) will take time, influencing their cautious rating.

BMO Capital Markets initiated coverage on Lululemon Athletica Inc. with an "underperform" rating, citing a deeply challenged business, declining market share to rivals, and deteriorating sales in key regions. Analyst Kelly Crago believes the athletic wear company's turnaround will be difficult due to stale products, diminishing relevance among consumers, and a shift away from athleisure fashion, forecasting further stock declines and pressure on margins. Despite a new CEO, Heidi O’Neill, tasked with revitalizing the brand, BMO sees Lululemon's stock potentially bottoming at $50 given current market conditions and lack of clear turnaround visibility.

Alexandria Real Estate Equities Inc., a life sciences landlord, has successfully defended against an investor lawsuit alleging that the company concealed weakening property values and delayed recording billions in losses. A US District Court judge dismissed the proposed class action, ruling that the plaintiff failed to sufficiently prove that the REIT's executives intentionally or recklessly misled investors. The court found that the investor did not adequately link the executives to the company's accounting analyses or impairment procedures.

This article announces that Alliance Entertainment Holding Corp filed a Form 8K on September 10. The filing is available for review on Investing.com. The article itself provides minimal detail beyond the announcement.

Alliance Entertainment (NASDAQ: AENT) reported robust fiscal year 2026 results, with an 8% revenue increase to $1.15 billion and a 24% rise in adjusted diluted EPS to $0.46, driven by strong demand for physical entertainment media and collectibles. The company's shares rallied significantly following the announcement, reflecting investor confidence in its strategic shift towards premium collectibles, authentication platforms, and technological advancements like AI and automation. While facing challenges such as negative operating cash flow due to working capital demands, Alliance Entertainment aims to continue its growth trajectory by leveraging studio partnerships, expanding its exclusive distribution network, and enhancing operational efficiency.

TJX (TJX) has seen a 17.8% decline in its stock price over the last four weeks, but indicators suggest a potential trend reversal. Its Relative Strength Index (RSI) of 17.78 indicates the stock is oversold, while a 0.6% increase in consensus EPS estimates for the current year, driven by analyst revisions, points to a fundamental improvement. Additionally, the stock holds a Zacks Rank #2 (Buy), further supporting the likelihood of a near-term rebound.

Turn Therapeutics Inc. will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026, at 1:30 PM ET. CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will discuss the company's atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and findings across diverse patient populations. A live webcast and replay will be available on the company's investor relations website.

Surging diesel prices, which have surpassed $6 a gallon, could significantly boost the demand for Tesla's electric semi-trucks, according to Morgan Stanley analysts. An autonomous electric semi is projected to cut costs by 20% per mile and increase annual mileage by 133% compared to human-operated diesel vehicles. This could lead to a dramatic increase in profit per truck, making Tesla's trucking solution more attractive amidst rising fuel costs.

Morgan Stanley suggests that Tesla's autonomous trucking software could generate $17 billion in revenue and $7.5 billion in incremental EBIT by 2040, based on a projected $500 billion to $1.1 trillion U.S. autonomous trucking market by 2041. The firm estimates that the software could yield $12,000 to $18,000 in monthly revenue per truck, assuming Tesla has 82,000 Semis on the road. Despite this potential, Tesla's shares are down over 19% year-to-date, making it the worst-performing stock among the "Magnificent 7."